May 11, 2026 | CSL Flags $5B Vifor Impairment as Shares Hit Nine-Year Low

CSL's $5B write-down from the Vifor Pharma acquisition sends shares to a nine-year low — the largest single-day drop on record. Inhibrx's INBRX-106 posts 44% ORR vs Keytruda's 21% in head and neck cancer. PlusRezdiffra clears $311M in Q1, Fractyl's GLP-1 gene therapy gets European clinical trial greenlight, and Daiichi Sankyo targets global top-5 oncology by 2035.visit us at www.thepharmacloseout.com pharma, pharmaceutical, FDA, clinical trials, biotech, drugapprovals, healthcare, pharma podcast, The Pharma Closeout, CSL, Vifor Pharma,INBRX-106, Inhibrx Biosciences, Keytruda, pembrolizumab, Merck, HNSCC, head andneck cancer, Rezdiffra, resmetirom, Madrigal Pharmaceuticals, MASH, FractylHealth, GLP-1 gene therapy, Eli Lilly, Mounjaro, Zepbound, Daiichi Sankyo,Enhertu, ADC, antibody-drug conjugate, Bizengri, zenocutuzumab, NRG1, CNPV,GSK, Sino Biopharmaceutical, bepirovirsen, hepatitis B, Braveheart Bio, Hengrui, hypertrophic cardiomyopathy, Lilly